Dyslipidemia management in primary prevention of cardiovascular disease:Current guidelines and strategies

作     者：Aditya D Hendrani Tolulope Adesiyun Renato Quispe Steven R Jones Neil J Stone Roger S Blumenthal Seth S Martin 

作者机构：Department of MedicineMedstar Union Memorial Hospital Ciccarone Center for the Prevention of Heart DiseaseDivision of CardiologyDepartment of MedicineJohns Hopkins University School of Medicine Division of CardiologyNorthwestern University Feinberg School of Medicine 

出 版 物：《World Journal of Cardiology》 (世界心脏病学杂志（英文版）（电子版）)

年 卷 期：2016年第8卷第2期

页      面：201-210页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Dyslipidemia Guidelines Cardiovascular diseases 

摘      要：Cardiovascular disease is the leading cause of death in the United States. In 2010, the Centers for Disease Control and Prevention estimated that $444 billion was spent on cardiovascular diseases alone, about $1 of every $6 spent on health care. As life expectancy continues to increase, this annual cost will also increase, making costeffective primary prevention of cardiovascular disease highly desirable. Because of its role in development of atherosclerosis and clinical events, dyslipidemia management is a high priority in cardiovascular prevention. Multiple major dyslipidemia guidelines have been published around the world recently, four of them by independent organizations in the United States alone. They share the goal of providing clinical guidance on optimal dyslipidemia management, but guidelines differ in their emphasis on pharmacotherapy, stratification of groups, emphasis on lifestyle modification, and use of a fixed target or percentage reduction in low density lipoprotein cholesterol. This review summarizes eight major guidelines for dyslipidemia management and considers the basis for their recommendations. Our primary aim is to enhance understanding of dyslipidemia management guidelines in patient care for primary prevention of future cardiovascular risk.